Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Miscellaneous · ·
$57.65
▲ $0.18 (+0.3%)
Market data updated: 09/20 03:00 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
Not available
Day Range
$57.07 - $57.84
52-Week Range
$48.26 - $73.01
Beta
—
Next Earnings
16.11.2026
Support
$48.26
Resistance
$66.62
-20.0% (1Y)
Strengths: 8/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $70.55 vs. price $57.65 (+22.4%)
Fair Value
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: -0.25 (3y annualized return -11.2% / max drawdown 45.7%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
54
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
48
Quality
58
Value
62
Momentum
26
Risk
48
Sentiment
100
Fundamental
66
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Dolby Laboratories highlights its strategic expansion into emerging markets and leadership shifts. The company announced CEO Kevin Yeaman’s retirement and the appointment of Marc Whitten as his successor, marking a new leadership chapter. Additionally, Dolby is diversifying its presence by partnering with automotive firms for in-car gaming and live sports streaming, while also collaborating with the Seattle Seahawks for immersive sports technology. Industry analysts emphasize Dolby’s focus on innovation amid broader audio-video market challenges.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Dolby Laboratories. News trend score: 100. Reason: 12 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
19
🎯 Conviction (vs. Emotion)
40
Psychology
43
Fundamentals
66
Technical
26
Valuation
62
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+10%
Market Narrative
45
Fundamental Reality
40
Narrative Gap
+5
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
DLB’s psychology is fragmented, with **herding** (27) as the dominant signal—evidenced by peer underperformance despite identical positive sentiment. The **euphoria** score (19) suggests traders may overvalue fundamentals (9.4% above 200-day average) while ignoring valuation gaps (-12% vs. DCF). The **narrative gap** (14) hints at a disconnect: traders’ optimism (54) exceeds objective reality (40), possibly fueling herd-driven buying. The key question: *Is the lagging momentum (-1.2% ROC) a temporary pause or a sign of overvaluation?*
Updated: 09/07/2026, 02:39 PM
What could change this?
👥 What the crowd believes
"Dolby Laboratories is partnering with Cinemo GmbH and SmashLabs to bring immersive gaming to in-vehicle entertainment systems"
"Kevin Yeaman retires after nearly two decades, Marc Whitten appointed as new CEO"
📈 13D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Jesse Livermore — 19/100
🗣️ Why do they disagree?
The stark contrast between Walter Bagehot’s near-perfect score and Peter Lynch’s rejection highlights how DLB’s perceived strengths and weaknesses clash across methodologies. Bagehot’s near-universal endorsement—rooted in liquidity and resilience—stands in sharp relief to Lynch’s dismissal, which prioritizes high-growth potential at a reasonable valuation, a trait DLB lacks in his framework. Meanwhile, the middle-ground scores from Fisher, Smith, and Nelson suggest DLB could be a solid long-term hold for patient investors, but not an exceptional pick. Marks and Livermore’s caution reflects skepticism about overvaluation or unclear momentum, while the efficient-market camp’s lukewarm verdict implies DLB’s case for outperformance is thin. Even Veblen’s low score hints at potential speculative overreach, contrasting with Bagehot’s institutional stability lens.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 95
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 79
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 68
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 68
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 63
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 63
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 56
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 56
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 53
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 41
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 40
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 37
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 27
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 19
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
88.1%
Operating Margin
19.6%
Net Margin
18.9%
EBITDA Margin
26.1%
ROE
9.7%
ROA
7.9%
ROIC
—
EPS
$2.66
Cash
$701.89M
Total Debt
—
Current Ratio
3.17
Debt/Equity
—
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 11.8.2026 | $0.360 |
| 12.5.2026 | $0.360 |
| 11.5.2026 | $0.360 |
| 10.2.2026 | $0.360 |
| 9.2.2026 | $0.360 |
| 2.12.2025 | $0.360 |
| 1.12.2025 | $0.360 |
| 12.8.2025 | $0.330 |
| 11.8.2025 | $0.330 |
| 13.5.2025 | $0.330 |
| 12.5.2025 | $0.330 |
| 11.2.2025 | $0.330 |
How is Fair Value calculated? →
Current Price
$57.65
Estimated Fair Value (DCF)
$70.55
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+22.4%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
2.5%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 2.5% | $446.87M | $409.97M |
| 2 | 2.5% | $458.13M | $385.60M |
| 3 | 2.5% | $469.65M | $362.65M |
| 4 | 2.5% | $481.42M | $341.05M |
| 5 | 2.5% | $493.46M | $320.71M |
Base FCF (last actual year)
$435.85M
Terminal Value
$7.78B
Present Value of Terminal Value
$5.06B
Enterprise Value
$6.88B
Net Debt
$0
Equity Value
$6.88B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$26.90
Tangible Book Value per Share (Tangible NAV)
$17.39
Sentiment based on basic keywords (not AI) — 12 positive, 6 neutral, 2 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 17.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 10.9.2026
PR Newswire · 10.9.2026
Yahoo · 1.9.2026
Zacks · 1.9.2026
Yahoo · 31.8.2026
Zacks · 31.8.2026
Yahoo · 27.8.2026
MT Newswires · 27.8.2026
PR Newswire · 27.8.2026
Yahoo · 27.8.2026
Simply Wall St. · 27.8.2026
Yahoo · 26.8.2026
Zacks · 26.8.2026
Yahoo · 21.8.2026
MT Newswires · 21.8.2026
Business Wire · 21.8.2026
Dolby Laboratories (DLB) currently has a StockIQ AI score of 54/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
DLB currently scores 54/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, DLB's estimated fair value is $70.55, which is 22.4% above the current price of $57.65. This is one valuation model among several signals in the fair-value category, not a price target.
DLB's technical score is 26/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $70.55 vs. price $57.65 (+22.4%); Free cash flow growth: 46.6%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: Calmar: -0.25 (3y annualized return -11.2% / max drawdown 45.7%); Earnings per share (EPS) growth: -2.6%; Net income growth: -2.6%.
Yes — DLB has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 10 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Couling John D | Open Market Sale | 1.9.2026 | 7,667 | -7,667 | $61.05 |
| Couling John D | Exercise of Derivative Securities | 1.9.2026 | 7,667 | -7,667 | — |
| Couling John D | Exercise of Derivative Securities | 1.9.2026 | 7,667 | +7,667 | $45.50 |
| Dolby Dagmar | Gift | 28.8.2026 | 0 | -300,000 | — |
| Dolby Dagmar | Gift | 28.8.2026 | 1,000,000 | +1,000,000 | — |
| Dolby Dagmar | Gift | 28.8.2026 | 4,672,117 | -2,000,000 | — |
| Dolby Dagmar | Conversion of Derivative Security | 28.8.2026 | 300,000 | +300,000 | — |
| Dolby Dagmar | Conversion of Derivative Security | 28.8.2026 | 4,372,117 | -300,000 | — |
| Dolby Dagmar | Conversion of Derivative Security | 28.8.2026 | 300,000 | -300,000 | — |
| Dolby Dagmar | Gift | 28.8.2026 | 2,000,000 | -2,000,000 | — |
| Dolby Dagmar | Gift | 28.8.2026 | 1,000,000 | +1,000,000 | — |
| Dolby Dagmar | Gift | 28.8.2026 | 300,000 | -300,000 | — |
| Dolby Dagmar | Gift | 28.8.2026 | 1,000,000 | +1,000,000 | — |
| Dolby Dagmar | Conversion of Derivative Security | 28.8.2026 | 300,000 | +300,000 | — |
| Nicholson Ryan | Open Market Sale | 25.8.2026 | 34,453 | -1,183 | $65.28 |
| Nicholson Ryan | Open Market Sale | 25.8.2026 | 1,183 | -1,183 | $65.28 |
| Revankar Shriram | Open Market Sale | 14.8.2026 | 3,000 | -3,000 | $62.71 |
| Nicholson Ryan | Open Market Sale | 10.8.2026 | 1,348 | -1,348 | $62.04 |
| Nicholson Ryan | Open Market Sale | 10.8.2026 | 35,636 | -1,348 | $62.04 |
| Nicholson Ryan | Open Market Sale | 4.8.2026 | 357 | -357 | $60.63 |
| Nicholson Ryan | Open Market Sale | 4.8.2026 | 36,984 | -357 | $60.63 |
| Couling John D | Exercise of Derivative Securities | 3.8.2026 | 7,667 | -7,667 | — |
| Couling John D | Exercise of Derivative Securities | 3.8.2026 | 7,667 | +7,667 | $45.50 |
| Couling John D | Open Market Sale | 3.8.2026 | 783 | -783 | $59.03 |
| Couling John D | Open Market Sale | 3.8.2026 | 6,884 | -6,884 | $60.11 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,532,041 shares short as of 2026-08-31 · vs. 6,301,569 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
59.7% of trading volume this week was short selling, vs. 78.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology